| Literature DB >> 28208575 |
Dongxu Xing1,2, Qiong Yang3, Liang Jiang4, Qingrong Li5, Yang Xiao6, Mingqiang Ye7, Qingyou Xia8.
Abstract
The silkworm Bombyx mori is an economically important species. White muscardine caused by Beauveria bassiana is the main fungal disease in sericulture, and understanding the silkworm responses to B. bassiana infection is of particular interest. Herein, we investigated the molecular mechanisms underlying these responses in two silkworm strains Haoyue (HY, sensitive to B. bassiana) and Kang 8 (K8, resistant to B. bassiana) using an RNA-seq approach. For each strain, three biological replicates for immersion treatment, two replicates for injection treatment and three untreated controls were collected to generate 16 libraries for sequencing. Differentially expressed genes (DEGs) between treated samples and untreated controls, and between the two silkworm strains, were identified. DEGs and the enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways of the two strains exhibited an obvious difference. Several genes encoding cuticle proteins, serine proteinase inhibitors (SPI) and antimicrobial peptides (AMP) and the drug metabolism pathway involved in toxin detoxification were considered to be related to the resistance of K8 to B. bassiana. These results revealed insight into the resistance and susceptibility of two silkworm strains against B. bassiana infection and provided a roadmap for silkworm molecular breeding to enhance its resistance to B. bassiana.Entities:
Keywords: Beauveria bassiana; RNA-seq; resistance; silkworm
Mesh:
Year: 2017 PMID: 28208575 PMCID: PMC5343773 DOI: 10.3390/ijms18020234
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Survival curves of K8 and Haoyue (HY) strains infected by B. bassiana: (A) immersion treatment using a conidial suspension of 1 × 105 conidia/mL; and (B) immersion treatment using a conidial suspension of 5 × 105 conidia/mL. Error bars: SE of the mean. p represents the statistically significantly different value.
Summary of sequencing data.
| Sample | Raw Reads | Clean Reads | Clean Base | Total Mapped | Total Mapped Ratio | Unique Match |
|---|---|---|---|---|---|---|
| HY-control-1 | 14,538,847 | 14,283,926 | 714,196,300 | 12,821,136 | 89.76% | 48.20% |
| HY-control-2 | 13,093,162 | 12,957,649 | 647,882,450 | 11,439,009 | 88.28% | 53.63% |
| HY-control-3 | 14,750,894 | 14,604,137 | 730,206,850 | 12,986,072 | 88.92% | 62.05% |
| HY-immersion-1 | 18,735,786 | 18,318,940 | 915,947,000 | 16,445,941 | 89.78% | 52.31% |
| HY-immersion-2 | 14,899,363 | 14,591,964 | 729,598,200 | 13,070,880 | 89.58% | 51.16% |
| HY-immersion-3 | 12,500,104 | 12,366,585 | 618,329,250 | 11,040,402 | 89.28% | 54.10% |
| HY-injection-1 | 15,171,911 | 14,914,968 | 745,748,400 | 13,195,864 | 88.47% | 74.54% |
| HY-injection-2 | 15,078,479 | 14,804,938 | 740,246,900 | 12,837,562 | 86.71% | 72.23% |
| K8-control-1 | 17,655,181 | 17,298,316 | 864,915,800 | 15,429,685 | 89.20% | 45.02% |
| K8-control-2 | 12,458,912 | 12,334,197 | 616,709,850 | 10,425,374 | 84.52% | 57.16% |
| K8-control-3 | 13,424,038 | 13,277,104 | 663,855,200 | 11,612,998 | 87.47% | 53.37% |
| K8-immersion-1 | 15,981,466 | 15,699,938 | 784,996,900 | 14,060,649 | 89.56% | 40.49% |
| K8-immersion-2 | 17,412,127 | 17,068,312 | 853,415,600 | 15,368,966 | 90.04% | 50.74% |
| K8-immersion-3 | 12,750,866 | 12,610,756 | 630,537,800 | 11,102,951 | 88.04% | 47.15% |
| K8-injection-1 | 14,183,649 | 13,929,356 | 696,467,800 | 12,446,506 | 89.35% | 74.64% |
| K8-injection-2 | 14,573,110 | 14,328,895 | 716,444,750 | 12,705,750 | 88.67% | 74.15% |
| Average | 14,825,493 | 14,586,874 | 729,343,691 | 12,936,859 | 88.60% | 56.93% |
Figure 2Statistics of differentially expressed genes (DEGs) in K8 and HY strains: (A) number of up-regulated and down-regulated DEGs; (B) Venn plot of DEGs in K8 and HY in the immersion experiment; (C) Venn plot of DEGs in K8 and HY in the injection experiment; (D) Venn plot of DEGs in K8 in immersion and injection experiments; and (E) Venn plot of DEGs in HY in immersion and injection experiments.
Figure 3Verification of RNA-Seq results by qPCR: (A) expression patterns of six randomly selected DEGs identified in the immersion experiment; and (B) expression patterns of six randomly selected DEGs identified in the injection experiment. BGIBMGA007184: cytochrome P450 protein. BGIBMGA006280: cecropin A. BGIBMGA009094: BmSPI38. BGIBMGA004541: heat shock protein hsp20.4. BGIBMGA004401: 30K lipoprotein 19G1 precursor. BGIBMGA007184: heat shock protein hsp20.8.
Figure 4Functional classification of DEGs identified in the immersion experiment: (A) up-regulated genes; and (B) down-regulated genes. SPI, serine protease inhibitor; lipoprotein (30K protein), lepidopteran low molecular weight lipoprotein (30K protein); PBP/GOBP, insect pheromone/odorant binding protein; AMP, antimicrobial peptide; MFS, major facilitator superfamily; PGRP, peptidoglycan recognition protein; PBP/GOBP, pheromone binding protein/general odorant binding protein.
Figure 5Functional classification of DEGs identified in the injection experiment: (A) up-regulated genes; and (B) down-regulated genes. Lipoprotein (30K protein), lepidopteran low molecular weight lipoprotein (30K protein); PBP/GOBP, insect pheromone/odorant binding protein; AMP, antimicrobial peptide; MFS, major facilitator superfamily.
KEGG pathway enrichment analysis.
| Pathway ID | Description | ||||
|---|---|---|---|---|---|
| Immersion | Injection | ||||
| K8 | HY | K8 | HY | ||
| ko00232 | Caffeine metabolism | 0.0045 | |||
| ko04974 | Protein digestion and absorption | 0.0266 | |||
| ko00020 | Tricarboxylic acid (TCA) cycle | 0.0304 | 0.0340 | ||
| ko04972 | Pancreatic secretion | 0.0353 | 0.0410 | ||
| ko00720 | Carbon fixation pathways in prokaryotes | 0.0494 | |||
| ko00052 | Galactose metabolism | 0.0011 | |||
| ko04512 | ECM-receptor interaction | 0.0158 | 0.0214 | ||
| ko00561 | Glycerolipid metabolism | 0.0221 | 0.0087 | ||
| ko04145 | Phagosome | 0.0404 | 0.0006 | 3.9 × 10−5 | |
| ko04142 | Lysosome | 0.0452 | 0.0001 | ||
| ko00603 | Glycosphingolipid biosynthesis—globo series | 0.0469 | |||
| ko00531 | Glycosaminoglycan degradation | 0.0469 | |||
| ko00604 | Glycosphingolipid biosynthesis—ganglio series | 0.0469 | |||
| ko04711 | Circadian rhythm—fly | 0.0004 | 0.0294 | ||
| ko05130 | Pathogenic Escherichia coli infection | 0.0007 | 0.0119 | ||
| ko00511 | Other glycan degradation | 0.0024 | 0.0023 | ||
| ko05215 | Prostate cancer | 0.0041 | 0.0381 | ||
| ko04919 | Thyroid hormone signaling pathway | 0.0062 | 0.0496 | ||
| ko04390 | Hippo signaling pathway | 0.0088 | |||
| ko04975 | Fat digestion and absorption | 0.0105 | |||
| ko05166 | Human T-cell lymphotropic virus I (HTLV-I) infection | 0.0105 | 0.0486 | ||
| ko04612 | Antigen processing and presentation | 0.0115 | 0.0109 | ||
| ko05200 | Pathways in cancer | 0.0118 | |||
| ko05217 | Basal cell carcinoma | 0.0126 | |||
| ko00010 | Glycolysis/Gluconeogenesis | 0.0130 | |||
| ko05164 | Influenza A | 0.0138 | 0.0128 | ||
| ko04151 | PI3K-Akt signaling pathway | 0.0155 | 0.0141 | ||
| ko04391 | Hippo signaling pathway—fly | 0.0179 | |||
| ko04621 | Nucleotide-binding oligomerization domain (NOD)-like receptor signaling pathway | 0.0179 | |||
| ko00591 | Linoleic acid metabolism | 0.0186 | |||
| ko00565 | Ether lipid metabolism | 0.0192 | |||
| ko04141 | Protein processing in endoplasmic reticulum | 0.0199 | 0.0025 | ||
| ko04510 | Focal adhesion | 0.0206 | |||
| ko04662 | B cell receptor signaling pathway | 0.0226 | 0.0214 | ||
| ko03320 | Peroxisome proliferator-activated receptor (PPAR) signaling pathway | 0.0255 | 0.0242 | ||
| ko05131 | Shigellosis | 0.0270 | |||
| ko00592 | α-Linolenic acid metabolism | 0.0270 | |||
| ko00600 | Sphingolipid metabolism | 0.0278 | |||
| ko05169 | Epstein-Barr virus infection | 0.0280 | 0.0260 | ||
| ko05205 | Proteoglycans in cancer | 0.0284 | |||
| ko05222 | Small cell lung cancer | 0.0301 | 0.0285 | ||
| ko04014 | Ras signaling pathway | 0.0306 | |||
| ko04540 | Gap junction | 0.0309 | 0.0293 | ||
| ko05134 | Legionellosis | 0.0309 | |||
| ko04146 | Peroxisome | 0.0325 | |||
| ko04916 | Melanogenesis | 0.0333 | |||
| ko04144 | Endocytosis | 0.0352 | |||
| ko01040 | Biosynthesis of unsaturated fatty acids | 0.0419 | |||
| ko05160 | Hepatitis C | 0.0456 | 0.0433 | ||
| ko04660 | T cell receptor signaling pathway | 0.0465 | 0.0441 | ||
| ko04910 | Insulin signaling pathway | 0.0484 | 0.0459 | ||
| ko04931 | Insulin resistance | 0.0055 | |||
| ko05145 | Toxoplasmosis | 0.0062 | |||
| ko05162 | Measles | 0.0094 | |||
| ko00310 | Lysine degradation | 0.0118 | |||
| ko04623 | Cytosolic DNA-sensing pathway | 0.0170 | |||
| ko00380 | Tryptophan metabolism | 0.0181 | |||
| ko05110 | Vibrio cholerae infection | 0.0201 | |||
| ko04920 | Adipocytokine signaling pathway | 0.0221 | |||
| ko05323 | Rheumatoid arthritis | 0.0285 | |||
KEGG pathways containing genes differentially expressed in K8 and HY strains.
| KEGG Term | Corrected | |
|---|---|---|
| ko04622:RIG-I-like receptor signaling pathway | 0.0005 | 0.0459 |
| ko00983:Drug metabolism—other enzymes | 0.0012 | 0.0459 |
| ko00830:Retinol metabolism | 0.0012 | 0.0459 |
Genes specifically expressed in the K8 strain.
| Name | Length | KO Name | KO ID | Description |
|---|---|---|---|---|
| BGIBMGA004606 | 507 | - | - | Heat shock protein hsp20.4 [Bombyx mori] |
| BGIBMGA004882 | 759 | - | - | bmp-2 [Bombyx mori] |
| BGIBMGA013238 | 1347 | - | - | P450 6B5-like|cytochrome P450 CYP6AE7 [Bombyx mori] |
| BGIBMGA003907 | 402 | CYP3A | K07424 | Cytochrome P450 |
| BGIBMGA003908 | 1044 | CYP9 | K15003 | P450 9e2-like|E-class P450, group II; Cytochrome P450 |
| BGIBMGA010047 | 810 | - | - | Quinoprotein amine dehydrogenase, β chain-like |
Figure 6Validation of K8-specific expressed genes by qPCR: (A) RNA-Seq results of P450 6B5-like and P450 9e2-like; and (B) qPCR results of P450 6B5-like and P450 9e2-like.